Form 483

BeiGene, USA Inc. Form 483, 2023-11-13

FDA issued a Form 483 to BeiGene, USA Inc. on 2023-11-13 with 3 public-safe observations.

483· Form 483 issuedHuman Drugs3 observations

BeiGene, USA Inc. · San Mateo, United States · Issued November 13, 2023

Overview

  • 3 public-safe observations are available for this inspection.
  • 3 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

13 Nov 2023
21 CFR 312.50

General responsibilities of sponsors

Cited by Scott N Lim

13 Nov 2023
21 CFR 314.80(b)

Failure to develop written procedures

Cited by Scott N Lim

13 Nov 2023
21 CFR 314.80(c)(1)(i)

Late submission of 15-day report

Cited by Scott N Lim

Inspected site

BUBeiGene, USA Inc.San Mateo, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 312.50Cited across public-safe Form 483 observations1x
21 CFR 314.80(b)Cited across public-safe Form 483 observations1x
21 CFR 314.80(c)(1)(i)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 3 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere